The yeast Candida albicans is the leading cause of disseminated fungal infection in neonates, immunocompromised hosts, diabetics, and postoperative patients; Candida tropicalis is the second most frequent isolate. Because the integrin analogue in C. albicans shares antigenic, structural, and functional homologies with the 132-integrin subunits aM and ax, we investigated the role of integrin analogues in epithelial adhesion of C. albicans and C. tropicalis.
Introduction
The yeast Candida albicans is the leading cause of disseminated fungal infection in the immunocompromised host, the diabetic, the neonate, and the postoperative patient. In representative studies of fungemia in each of these patient populations, C. albicans accounts for 60-80% of isolates and C. tropicalis for 12-20% ofisolates, whereas other less pathogenic Candida species including C. parapsilosis, C. glabrata, and C. krusei are cumulatively identified < 20% of the time (1) (2) (3) (4) (5) (6) . Genetically related yeasts such as Saccharomyces cerevisiae are even less frequently implicated in invasive disease (7) . Similar results obtain when colonizing flora are enumerated; in one series in cancer patients, C. albicans was present in 68% of isolates from sites other than blood, while C. tropicalis, C. glabrata, C. parapsilosis, C. krusei, and S. cerevisiae accounted for 12.3%, 10.3%, 3.0%, 1.5%, and 0.8% ofisolates, respectively (8) . Thus, in a hierarchy of pathogenicity, the invasive potential of C. albicans and C. tropicalis-and the lesser virulence of related species-appears to reflect their relative abilities to colonize the human host.
The site of initial contact between Candida and the host is thought to be the epithelium ofthe gastrointestinal or genitourinary tract, and at least two studies have shown preferential adhesion by C. albicans, as opposed to other Candida species, to exfoliated buccal or vaginal epithelial cells (9, 10) ; a number of surface carbohydrates (e.g., those of ABO or Lewisa blood group antigens) have been proposed as target molecules on the epithelial cell ( 11) . However, we thought it possible that protein-protein interactions might provide a more general mechanism of candidal adhesion. For example, the integrin analogue in C. albicans shares antigenic, structural, and functional homologies with aM and ax of the 32-integrin subset. As previously demonstrated, iC3b-coated sheep erythrocytes and mAbs recognizing aM bound specifically to both yeast-and hyphal-phase C. albicans (12) (13) (14) (15) . Immunodetection with the mAb anti-Mo 1 identified a major band ofMr 165+15 kD after SDS-PAGE and Western blotting of C. albicans cytosolic extracts under nonreducing conditions, a mass consistent with that reported for aM and ax (16, 17) . Moreover, C3 fragment iC3b, an identified ligand for aMf2 and ax #2 dimers, bound saturably and reversibly to C. albicans with a Ka virtually identical to that established for the binding of iC3b to these integrins on human neutrophils ( 14, 18) .
In mammalian cells, the f2-integrins also regulate the adhesion of leukocytes to endothelium by recognition ofthe tripep-tide sequence arginine-glycine-aspartic acid (RGD)' (19) (20) (21) ; RGD peptides have been shown to inhibit this interaction (22) . We have previously demonstrated a similar function for the integrin analogue in C. albicans in mediating adhesion to human umbilical vein endothelium (23) . In these earlier studies, the degree of surface expression of the integrin analogue in C. albicans correlated directly with adhesion to the endothelial monolayer; specific adhesion was inhibited by 50-80% with the use of mAbs recognizing aM or with purified iC3b (23) .
Given these intriguing homologies, we therefore sought to correlate surface expression of the integrin analogue with epithelial adhesion for the two most pathogenic yeasts, C. albicans and C. tropicalis, and to identify those components on the microorganism and on the epithelial cell which mediate this interaction. Assuredly, a better understanding of the mechanisms by which C. albicans and other pathogenic yeasts adhere to human epithelium could serve as a critical first step in the prevention ofdisseminated disease in an enlarging spectrum of susceptible hosts.
Methods
Growth and radiolabeling of yeast isolates. Organisms used in these experiments were isolated in pure culture from blood (Candida albicans [eight isolates], Candida tropicalis [three isolates]) of hospitalized patients and were identified in the Clinical Microbiological Laboratory of the University of Minnesota Hospital by morphology, germ tube expression, and multiple assimilation substrates on a yeast biochemical card (Automicrobic System, Vitek, Inc., Cleveland, OH). Growth curves for each isolate were determined spectrophotometrically by absorbance at 420 nm with simultaneous colony counts. Yeast cells were grown to exponential phase at 240C in Sabouraud's broth (Difco Laboratories, Inc., Detroit, MI) and were aliquoted and frozen at -70'C until use.
For each experiment, an aliquot of the desired isolate was grown overnight at 240C with rotation in a defined medium containing albumin, amino acids, and 20 mM D-glucose (23 Culture ofthe human epithelial cell line. HeLa S3, a cervical epithelioid carcinoma cell line (ATCC CCL 2.2), was maintained in continuous culture in Ham's F-12 medium (Life Technologies, Inc., Grand Island, NY) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 ig/ml streptomycin, and 2 mM L-glutamine. For use in the adhesion assay, I ml of epithelial cells at a concentration of 4 x I05 cells/ml was inoculated into each well of a 24-well plate (Costar Data Packaging Corp., Cambridge, MA), and grown over 48 h to a confluent monolayer in the same medium. Confluence was assessed by visual inspection using a Nikon inverted microscope.
Adhesion assay. The adhesion assay was modified from our previously published methods for adhesion to human umbilical vein endothelium (23) . A representative isolate of each Candida species was grown in the defined medium, labeled with [35S]methionine, washed five times in PBS, and resuspended in HBSS with calcium and magnesium, to which was added 1% BSA (HBSS'+/BSA). The C3 fragments iC3b and C3d were then isolated according to published methods (18, 26) . Fibronectin was purified from plasma by chromatography on gelatin-Sepharose (Pharmacia), according to the methods of Regnault et al. (27) . The isolation of fibronectin was confirmed by Western blot analysis using goat antiserum to human fibronectin (Atlantic Antibodies, Stillwater, MN).
Peptides. A 15-mer peptide, EIATRYRGDQDATMS, which encompasses the RGD site in iC3b (amino acid residues 1387-1401) and a control 15-mer peptide with the substitution of arginine-glycine-lysine (RGK) for RGD, were the gifts of Dr. John Lambris (Department of Pathology, University of Pennsylvania, Philadelphia, PA). Flanking residues in both 15-mer peptides were identical to the iC3b sequence, save for the substitution of alanine for cysteine at amino acid residue 1389. Additional 100-mg quantities of the 15-mer RGD and RGK peptides were synthesized in the Microchemical Genetics Facility at the University of Minnesota on a model 9600 peptide synthesizer (MilliGen/Biosearch, Burlington, MA), with subsequent purification on a Spectrophysics HPLC (Hewlett-Packard Co., Palo Alto, CA). Amino acid analysis of the purified samples was done on a model 6300 amino acid analyzer (Beckman Instruments, Inc.) A series of smaller iC3b peptides-RGDQD, TRYRGD, TRYRGDQD, RGDQDATMS, TRYRGDQDAT, TRYRGKQD, and a 12-mer peptide, EIATRYQ-DATMS, which included only the flanking residues from the 15-mer peptide-were also synthesized by this facility. Two 7-mer peptides, GRGDSPG and GRADSPG (the former from within the cell-binding domain of fibronectin) were synthesized as above. PepTite 2000 (a proprietary 23-mer peptide containing the amino acid sequence-XXXGRGDSPASSKXXX-surrounding the RGD site in native fibronectin) was purchased from Telios Pharmaceuticals, San Diego, CA (28) .
Inhibition ofadhesion with anti-aM mAbs, iC3b, C3d,fbronectin, and peptides. Anti-Mo 1, an IgM mAb, was obtained from Coulter Immunology. mAb 17 (IgM) and mAb 44 (IgG2, ) were the kind gifts of Dr. Robert Todd (University of Michigan, Ann Arbor, MI) and were dialyzed into PBS before use (29) . OKM 1 was purchased and purified as described above. Yeast cells were preincubated with the anti-aM mAbs as previously described (23) . Briefly, 5 x 106 [35S]methioninelabeled yeast cells were incubated in suspension for 30 min at 4VC with either 400 ,g/ml anti-Mo 1, 2,000 gg/ml OKM 1, 300 gg/ml mAb 17, or 300 ,g/ml mAb 44; final volume was 50 zd. Yeasts were then pelleted, washed three times with PBS, and used in the adhesion assay described above.
Yeast cells were also preincubated with iC3b, C3d, fibronectin, or the synthetic peptides before use in the adhesion assay. 2.5 x 106 [35S] methionine-labeled C. albicans were incubated for 45 min at 370C on a rotating rack with purified human iC3b or purified human fibronectin at a concentration of0.01 mM ( 1.8 mg/ml iC3b and 4.8 mg/ml fibronectin) in a final volume of 50 jl; each experimental well was inoculated with 5 X 104 labeled yeast cells. For wells used to quantitate nonspecific binding, a 100-fold excess (5.0 X 106) of unlabeled C. albicans preincubated in 0.02 mM iC3b or fibronectin was inoculated. As additional controls in the iC3b inhibition experiments, labeled and unlabeled C. albicans were incubated with BSA (Sigma Chemical Co., St. Louis, MO) or purified C3d (an iC3b degradation fragment that does not contain the C3 RGD site) at the concentration and conditions described above. For the peptide inhibition studies, preliminary doseresponse experiments confirmed that 1.0 mg/ml was the optimal inhibitory concentration for all 12 peptides; all peptide inhibition experiments reported in this paper were therefore performed at this concentration. For studies with C. tropicalis, preincubation with purified human iC3b, purified human fibronectin, BSA or the synthetic peptides was performed in the same manner. For the experiments involving preincubation with multiple ligands, the yeast cells were first incubated with the specified peptide for 45 min at 25°C, and then for 45 min at 37°C with either iC3b or fibronectin, all at the same concentrations as described above. After preincubation, the adhesion assay and the calculation of specific adhesion were performed as previously de- scribed.
Immunofluorescence ofHeLa cells. 2 ml of HeLa cells at a concentration of 4 X IO' cells/ml in Ham's F-12 medium supplemented with 10% FBS, 100 U/ ml penicillin, 1 00 ig/ ml streptomycin, and 2 mM L-glutamine were added to each well of a six-well tissue culture plate (Costar) containing a sterile glass coverslip. Plates were then incubated at 37°C, 5% CO2 for 48 h. The cell-coated coverslips were washed twice with unsupplemented Ham's F-12 medium and incubated at 37°C, 5% CO2 for 4 h. The cell-coated coverslips were then washed twice with PBS, fixed by submersion in cold 95% ethanol for 2 min, and washed an additional two times with PBS. Cell-coated coverslips were then incubated with one of the following primary antibodies diluted as indicated in PBS/ 3% BSA: 1: 1,000 dilution ofgoat anti-human C3 (Atlantic Antibodies, Stillwater, MN), 1:10 dilution of mouse anti-human iC3b (Quidel, San Diego, CA), 1:100 dilution of goat anti-human fibronectin (Atlantic Antibodies), 1:100 dilution of goat anti-human neutrophil elastase (Behring Diagnostics, LaJolla, CA), or PBS/3% BSA alone, for 30 min at 37°C in 5% CO2. The cell-coated coverslips were then washed three times with PBS/3% BSA and were incubated for 45 min at 370 in 5% C02, with a 1:100 dilution of either rabbit anti-goat IgG conjugated to fluorescein isothiocyanate (Kallestad, Austin, TX) or goat F(ab')2 antibody to mouse IgM/IgG conjugated to fluorescein isothiocyanate (Tago Inc., Burlingame, CA), as appropriate for the primary antibody. The cell-coated coverslips were then washed three times with PBS, inverted onto a glass microscope slide pretreated with a drop of glycerol with 2.5% DABCO (Sigma) and examined under phase-contrast and immunofluorescent microscopy (Laborlux 12; E. Leitz, Inc., Rockleigh, NJ) at x400.
Inhibition ofadhesion with polyclonal anti-C3 and anti-fibronectin antibodies. Goat anti-human C3 (Atlantic Antibodies) and goat antihuman fibronectin (Atlantic Antibodies), were each dialyzed against PBS at 4°C to remove azide. HeLa cell monolayers were washed twice with HBSS++, once with HBSS++/BSA, and then incubated with either a 1:2 dilution of the specified antibody solution in HBSS++/BSA or HBSS++/BSA alone, in a final volume of 250 ,ul for 60 min at 37°C. The antibody solution was then aspirated off the monolayers which were then washed twice with HBSS++/BSA and incubated with "S-labeled C. albicans or C. tropicalis in the adhesion assay.
Statistics. Results, expressed as mean±standard error unless otherwise noted, were analyzed using the Student's t test for unpaired samples. P < 0.05 was considered significant. 
Results
Surface expression of the integrin analogue and adhesion to human epithelium in C. albicans and C. tropicalis. Fig. 2 Fig. 2 B demonstrates that epithelial adhesion did not differ between C. albicans and C. tropicalis (44.0±1.9% for C. albicans vs. 38.8±3.6% for C. tropicalis [P = 0.180]). These results prompted us to examine the role of the integrin analogue in epithelial adhesion in C. albicans and to search for a different mechanism of adhesion in C. tropicalis.
Inhibition of epithelial adhesion of C. albicans with antiaM mAbs. Preincubation of C. albicans with mAb 17 (IgM) and mAb 44 (IgG2.) inhibited specific adhesion of C. albicans to the epithelial monolayer by 58.2% and 52.4%, respectively (P 0.005) (Fig. 3) . mAbs anti-Mol (IgM) and OKM1 (IgG2b) did not inhibit epithelial adhesion of C. albicans. We have previously shown that mAbs 17 and 44 significantly decrease the adhesion of C. albicans to human umbilical vein endothelium, while anti-Mo 1 is ineffective in this regard (23) . The inhibitory effects ofmAbs 17 and 44 suggest that epithelial adhesion in C. albicans is epitope-specific.
Inhibition ofepithelial adhesion ofC. albicans with purified proteins. The integrin aM/(2 recognizes RGD sites in at least two ligands: iC3b and fibrinogen ( 19, 30) . In addition, a fibronectin receptor in C. albicans has been implicated in endothelial adhesion (28, (31) (32) (33) . We therefore evaluated the ability of purified iC3b and fibronectin to inhibit epithelial adhesion in C. albicans. Controls for these experiments included the non-RGD-containing proteins BSA and C3d. As shown in Fig. 4 , adhesion of C. albicans preincubated with buffer alone was 43 .3+4.3%, while adhesion of yeast cells preincubated with BSA, C3d, or fibronectin was not significantly reduced. Adhesion of C. albicans preincubated with iC3b was reduced by 76.1% (P < 0.001). These results confirm that a significant proportion of epithelial adhesion in C. albicans is mediated by the integrin analogue and can be inhibited by its ligand, iC3b.
Inhibition of epithelial adhesion of C. albicans with synthetic peptides. The effects of synthetic peptides on candidal adhesion are shown in Table I . Two types of peptides were constructed and tested; group I peptides are derived from the RGD-site in iC3b, while group II peptides are derived from the RGD-site in fibronectin. Among the iC3b peptides, no significant inhibition of C. albicans adhesion was found with peptides < 8-mer or with either the 8-mer or the 15-mer RGK experiments with each purified protein.
peptides. However, C. albicans adhesion to human epithelium was inhibited by 21.3% after pretreatment with the 9-mer RGD peptide (P = 0.027), by 35.6% with the 10-mer RGD peptide (P = 0.001 ), and by 49.7% with the 15-mer RGD peptide (P <0.001). Two pieces of evidence indicate the importance of the flanking sequence in inhibition of epithelial adhesion. Firstly, the 12-mer peptide EIATRYQDATMS, which contains those sequences flanking the RGD site in iC3b, inhibited epithelial adhesion of C. albicans by 21.4% (P = 0.034). Secondly, the 1 5-mer RGK peptide, which also contains these flanking sequences, diminished C. albicans adhesion by -20% These results show that a 9-mer sequence encompassing the RGD-site and flanking residues in iC3b is sufficient for inhibition of C. albicans adhesion, but that maximal inhibition requires a longer flanking sequence ( 1 5-mer RGD peptide). The degree of inhibition observed with peptides containing iC3b flanking sequences, as well as the lack of inhibition with fibronectin peptides, support the contention that the amino acids surrounding the RGD site are also important in mediating adhesion of C. albicans to human epithelium. Such flanking sequences may provide specificity for recognition of target ligands by the integrin analogue in C. albicans.
Competitive inhibition studies provide additional evidence that the integrin analogue in C. albicans recognizes the RGD site in iC3b (Table II) . Preincubation of C. albicans with the 8-mer noninhibiting RGD-peptide nullified the inhibitory effect of iC3b (from 81.1% with iC3b alone to 17.1% after preincubation with the smaller peptide) (P = 0.001). These results confirm that the inhibition observed with iC3b is attributable to its RGD sequence and flanking residues, and not to charge or steric hindrance.
Inhibition ofepithelial adhesion ofC. tropicalis with purified proteins. Despite a low level of surface expression of the integrin analogue (24.2±3.8%, Fig. 2 A) , C. tropicalis did not differ significantly from C. albicans in adhesion to human epithelial monolayers in vitro (Fig. 2 B) . Therefore, in a separate series ofexperiments, we compared the effect ofiC3b and fibronectin on the adhesion of C. tropicalis (Fig. 5) . In contrast to results obtained with C. albicans, preincubation ofC. tropicalis with fibronectin reduced adhesion by 53.9% (P = 0.0 17), while iC3b was wholly ineffective. These results confirm that C. tropicalis, in which surface expression of the integrin analogue is significantly reduced, does not recognize iC3b as a ligand for adhesion.
Inhibition of epithelial adhesion of C. tropicalis with synthetic peptides. Table III shows the effects of synthetic peptides on the adhesion of C. tropicalis. As predicted from the studies with purified iC3b (Fig. 5) , pretreatment of C. tropicalis with iC3b-RGD peptides and their controls (group I) did not significantly inhibit epithelial adhesion. Conversely, preincubation of C. tropicalis with either oftwo RGD peptides from fibronectin, a proprietary -23-mer peptide (PepTite 2000) and a 7-mer peptide, decreased specific adhesion by 39.5% and 22.1%, respectively (P = 0.021 for the 23-mer and p = 0.003 for the 7-mer). Preincubation with a 7-mer arginine-alanine-aspartic acid (RAD) peptide had no effect. These results implicate the RGD site in fibronectin as the ligand for epithelial adhesion in C. tropicalis.
Competitive inhibition studies provide further support for this hypothesis, as shown in Table IV . Preincubation of C. tropicalis with the 7-mer fibronectin peptide before incubation with fibronectin itselfreduced the inhibitory effects offibronectin from 50.9% (fibronectin alone) to 16.7% (P = 0.002).
Immunofluorescence ofHeLa cells. If RGD-containing ligands such as iC3b and fibronectin are target sites for epithelial attachment of candidal species, then they must be present at the surface ofepithelial cells. Fig. 6 displays the immunofluores- identified those surface components of C. albicans and C. tropicalis that mediate epithelial adhesion, we next sought to confirm C3 and fibronectin as their respective targets on the epithelial cell. For C. albicans, pretreatment of the HeLa cell monolayer with a polyclonal antibody to C3 diminished adhesion by 27.3% (P = 0.002), while the anti-fibronectin antibody had no effect (Fig. 7) . The opposite results were found with C. tropicalis: pretreatment with anti-fibronectin antibodies reduced adhesion by 31.5% (P = 0.004), while anti-C3 antibodies were ineffective.
Discussion
Clinical experience attests to the ready adhesion of C. albicans to epithelial cells in the gastrointestinal and genitourinary tracts. In vitro, Candida species also adhere to a variety of epithelial cells, including exfoliated buccal and vaginal epithelial cells (9, 10, (35) (36) (37) (38) (39) (40) (41) (42) , as well as cultured cell lines such as HeLa S3, a cervical carcinoma (43) . A number of experimental observations suggest that adhesins in C. albicans are surface mannoproteins which are in turn induced by glucose, increased in expression in germinated cells, and inhibited by proteolytic enzymes (1 1, 35-42) . Hydrophobic interactions between candidal surface proteins and the host epithelial cell have also been implicated (44), as have been a variety of matrix proteins including fibronectin, laminin, and fibrinogen (31) (32) (33) (45) (46) (47) (48) . Binding sites for these extracellular matrix proteins have also been described on germ tubes or mycelia of C. albicans (46, 47) , but their presence in yeast-phase organisms is debated. C. albicans mutants that lack surface proteins Figure 6 . Immunofluorescent microscopy of HeLa S3 cells after incubation with a polyclonal antibody to human C3 (A), a murine monoclonal antibody against iC3b (B), a polyclonal antibody to human fibronectin (C), or a polyclonal antibody to human neutrophil elastase (D). In E, PBS/3%BSA was substituted for the primary antibody. These cells, cultured on glass coverslips, failed to form confluent monolayers, as compared to HeLa cells cultured in plastic microtiter plates. of 50-60 and 165 kD are less adherent to buccal epithelial cells (42) . In comparative studies with human or porcine endothelium, C. albicans and C. tropicalis were generally more adherent than other Candida species or S. cerevisiae (49, 50) , an indication that adhesion may well correlate strongly with pathogenicity.
As previously shown by us, expression of the integrin analogue in C. albicans is induced by glucose, inhibited by proteolytic enzymes, and exponentially increased after germination ( 14, 16) . Moreover, because of its antigenic, structural, and functional homologies with aM and ax, the integrin analogue in C. albicans also serves to mediate yeast adhesion to human endothelial cells (23) . Given these characteristics, the role of the integrin analogue as an epithelial adhesin is clearly deserving of study.
In mammalian cells, the ,32-integrins regulate the adhesion ofleukocytes by recognition ofthe tripeptide sequence RGD in proteins of the extracellular matrix (19) (20) (21) . The ligand specificity of the various integrins is based in part on the presence of differing flanking residues surrounding the RGD sequence in these matrix proteins (20, 21 ) . Our data support a similar role for the integrin analogue in C. albicans in mediating adhesion of this yeast to human epithelium. The polypeptide iC3b reduced the adhesion of C. albicans to human epithelium by 76%, while C3d (which does not contain the RGD site) and fibronectin (which does not contain the appropriate flanking residues) were ineffective. More precisely, 9-mer, 10-mer, and 1 5-mer peptides containing the iC3b RGD sequence with the appropriate flanking residues, and a 1 2-mer peptide consisting of only the flanking amino acids, significantly reduced adhesion by 21-50%. Maximal inhibition of adhesion to human epithelium was achieved with the 1 5-mer RGD peptide. Peptides less than eight amino acids in length, RGK-substituted peptides, and fibronectin-based RGD peptides without the appropriate iC3b flanking residues did not inhibit epithelial adhesion in C. albicans. Indeed, the 7-mer noninhibitory peptide used in these experiments is derived from the RGD site in fibronectin and has previously been reported to limit tissue dissemination in a murine model of C. albicans fungemia (51) . Taken together, these results suggest that the integrin analogue in C. albicans, like its mammalian counterpart, recognizes both the RGD tripeptide and specific flanking sequences in iC3b; the inefficacy ofthe 7-mer fibronectin peptide emphasizes that there are critical distinctions in the mechanisms by which C. albicans adheres to epithelium, as opposed to endothelium.
In several clinical studies of fungemia, C. tropicalis is the second most frequently isolated species (3, 8) . By flow cytome-C. albicans try, surface expression of the integrin analogue in C. tropicalis was low at 24.2±3.8% (Fig. 2 A) , and yet this yeast did not differ from C. albicans in its adhesion to human epithelium (Fig. 2 B) . Although iC3b and iC3b-RGD peptides did not significantly inhibit epithelial adhesion of C. tropicalis ( Fig. 5 and Table III (Fig. 5) . Fibronectin reduced the epithelial adhesion of C. tropicalis by 58%, while fibronectin-derived RGD peptides inhibited adhesion by 22-40% (Table III) . The smaller 7-mer fibronectin peptide-GRGDSPG-was minimally inhibitory at 22.1% (P = 0.003), while the larger 23-mer peptide (containing more of the appropriate fibronectin flanking sequences) had a greater effect (39.5% inhibition, P = 0.021). These results suggest that the degree of inhibition of C. tropicalis adhesion may be correlated with the number ofspecific amino acids to the left of the RGD sequence in the fibronectin peptides. Because a fibronectin receptor in C. albicans has recently been identified by ligand-binding studies (33) , characterization of a putative fibronectin receptor in C. tropicalis, delineation of its relationship to the 131-integrins, and more definitive studies of its role in epithelial adhesion are clearly warranted. For both C. albicans and C. tropicalis, double-blockade experiments demonstrated that preincubation with small RGD peptides (7-or 8-mer) was sufficient to nullify the effects ofthe larger ligands, either iC3b for C. albicans or fibronectin for C. tropicalis (Tables II and IV) . These results underscore the importance of the RGD-flanking sequence as a regulator of species-specific adhesion. Lastly, our immunofluorescent micrographs have indicated that both iC3b and fibronectin, two substrates for candidal adhesion, are present at the surface of the epithelial monolayer. These results confirm previous observations ofC3 synthesis in normal human keratinocytes and the epithelial cell lines A-431 (human epidermoid carcinoma), A-549 (human pulmonary carcinoma), and Hep G2 (human hepatocellular carcinoma) (52-55). Moreover, ELISA assay and immunoprecipitation in our laboratory have confirmed the synthesis ofC3 and its subsequent cleavage to iC3b by HeLa cells in serum-free medium (E. J. Michael and M. K. Hostetter, submitted for publication). Fibronectin, in turn, is synthesized by rat small intestine and is a well-established constituent ofsubendothelial extracellular matrix (20, 56, 57) . As we demonstrated, antibodies against iC3b inhibit epithelial adhesion in C. albicans, while anti-fibronectin antibodies have the identical effect for C. tropicalis.
In conclusion, these findings confirm that iC3b is the epithelial ligand for the integrin analogue in C. albicans, which recognizes the RGD tripeptide and definitive iC3b flanking sequences. Peptides encompassing the RGD site in iC3b and at least three flanking residues on either side inhibit this interaction. In contrast, fibronectin is the target protein for epithelial attachment of C. tropicalis, the second most prominent pathogenic isolate; fibronectin peptides are most effective in inhibiting this interaction. Understanding the mechanisms of epithelial adhesion in vitro may permit the design of highly specific peptides to inhibit epithelial adhesion of pathogenic Candida species in vivo, thereby enabling us to avert or at least to dimin- ish the colonization of patients with Candida species and the subsequent morbidity and mortality due to invasive infections with these organisms.
